Related Experiment Video
Updated: Jun 23, 2026

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
Automated characterisation of cerebral microbleeds using their size and spatial distribution on brain MRI
Vaanathi Sundaresan1, Giovanna Zamboni2,3, Robert A Dineen4,5
1Department of Computational and Data Sciences, Indian Institute of Science, Bengaluru, 560012, Karnataka, India.
Abstract:
Cerebral microbleeds (CMBs) are small, hypointense hemosiderin deposits in the brain measuring 2-10 mm in diameter. As one of the important biomarkers of small vessel disease, they have been associated with various neurodegenerative and cerebrovascular diseases. Hence, automated detection, and subsequent extraction of clinically useful metrics (e.g., size and spatial distribution) from CMBs are essential for investigating their clinical impact, especially in large-scale studies. While some work has been done for CMB segmentation, extraction of clinically relevant information is not yet explored. Herein, we propose the first automated method to characterise CMBs using their size and spatial distribution, i.e., CMB count in three regions (and their substructures) used in Microbleed Anatomical Rating Scale (MARS): infratentorial, deep, and lobar. Our method uses structural atlases of the brain for determining individual regions. On an intracerebral haemorrhage study dataset, we achieved a mean absolute error of 2.5 mm for size estimation and an overall accuracy > 90% for automated rating. The code and the atlas of MARS regions in Montreal Neurological Institute-MNI space are publicly available. RELEVANCE STATEMENT: Our method to automatically characterise cerebral microbleeds (size and location) showed a mean absolute error of 2.5 mm for size estimation and an over 90% accuracy for rating of infratentorial, deep and lobar regions. This is a promising approach to automatically provide clinically relevant cerebral microbleeds metrics. KEY POINTS: We present a method to automatically characterise cerebral microbleeds according to size and location. The method achieved a mean absolute error of 2.5 mm for size estimation. Automated rating for infratentorial, deep, and lobar regions achieved an over 90% overall accuracy. We made the code and atlas of Microbleed Anatomical Rating Scale regions publicly available.
Insights
We developed an automated method to measure cerebral microbleeds (CMBs) size and location, crucial for diagnosing small vessel disease. This tool achieved high accuracy, aiding clinical research in neurodegenerative and cerebrovascular conditions.
Area of Science:
- Neuroimaging
- Medical Image Analysis
- Neurology
Background:
- Cerebral microbleeds (CMBs) are key biomarkers for small vessel disease, linked to neurodegenerative and cerebrovascular conditions.
- Accurate CMB characterization (size, location) is vital for clinical impact studies, yet automated extraction of these metrics remains underexplored.
Purpose of the Study:
- To introduce the first automated method for characterizing CMBs by size and spatial distribution.
- To enable automated extraction of clinically relevant CMB metrics for large-scale research.
Main Methods:
- Developed an automated method utilizing structural brain atlases to define anatomical regions (infratentorial, deep, lobar) based on the Microbleed Anatomical Rating Scale (MARS).
- Applied the method to an intracerebral hemorrhage dataset for CMB size estimation and regional count analysis.
Main Results:
- Achieved a mean absolute error of 2.5 mm for CMB size estimation.
- Attained over 90% overall accuracy for automated CMB rating in infratentorial, deep, and lobar regions.
- Publicly released the code and MARS region atlas in MNI space.
Conclusions:
- The proposed automated method effectively characterizes cerebral microbleeds by size and location.
- This approach offers a promising solution for automatically generating clinically relevant CMB metrics, supporting research in cerebrovascular and neurodegenerative diseases.

